SynthesisThe journal of headache and pain2025
Distinct inflammatory profiles across migraine states: a systematic review and meta-analysis.
Synthesis in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Migraine in pediatric population: the role of biochemical markers.The journal of headache and pain · 2026Pooled it
- Cognitive impairment in vestibular migraine: a PubMed-based systematic review and meta-analysis.Frontiers in neurology · 2026Pooled it
- Integrated Identification of NAD⁺ Metabolism-Associated Candidate Genes.Molecular neurobiology · 2026Article
- Comment on 'IL-17A, IL-17RA, and IL-22 as biomarkers in migraine: associations with disease activity and clinical features'.Irish journal of medical science · 2026Article
- Determination of 8-OHdG and IL-6 Levels, and of APE1 and XRCC1 DNA Repair Gene Variants, in Patients with Migraine.Medicina (Kaunas, Lithuania) · 2026Article
- Plasma proteomics identifies proteins and pathways associated with incident migraine in 50,668 adults.The journal of headache and pain · 2026Article
- Extracellular Vesicles in Migraine: Biomarkers and Therapeutics.Molecular neurobiology · 2026Review
- Intranasal SARS-CoV-2 infection changes the transcriptome of the mouse trigeminal ganglion and brainstem: potential mechanisms underlying headache and trigeminal pain presentation in COVID-19.Journal of neuroinflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough several meta-analyses have emphasised the role of inflammation in migraine, none has accounted for the diversity of its clinical manifestations. This systematic review and meta-analysis aims to provide a comprehensive and reliable assessment of cytokine levels in migraine.
methodsWe systematically searched PubMed, Embase and Cochrane up to July 4-5, 2024. Original studies providing data on cytokine levels in migraine were included. Non-inclusion criteria covered studies on hemiplegic migraine, controls with tension-type headache, and unclear cytokine identification. The meta-analysis did not cover studies involving less than 10 participants per group or lacking accessible numeral data. Summary data were extracted from each study and pooled using a random-effects model. Standardized mean differences (SMD) were calculated to compare cytokine levels across all relevant biological samples and comparison groups.
findingsFifty-seven studies were included in the narrative review and/or meta-analysis, covering 2850 migraine patients and 2814 controls. In episodic migraine patients versus controls, blood levels of interleukin-6 (SMD 0·36 [95% CI, 0.07; 0·64], P = 0·013, I²=74·0%), transforming growth factor β (SMD 0·68 [95% CI, 0·44; 0·93], P < 0·001, I²=0·0%) and C-X-C motif ligand 8 (narrative review) were elevated. Levels of interleukin-6 (narrative review; SMD 1·40 [95% CI, 0·95; 1·86], P < 0.001, I²=0·0%) and adiponectin (SMD 0·59 [95% CI, 0·19; 0·98], P = 0·003, I²=36·0%) were elevated in chronic versus episodic migraine. Levels of interleukin-1β (SMD 0·53 [95% CI, 0·15; 0·91], P = 0·006, I²=0·0%), interleukin-10 (narrative review) and salivary levels of interleukin-6 (narrative review) were elevated in ictal versus interictal migraine. No differences were found in peripheral blood cytokine levels between migraine with aura and migraine without aura.
conclusionsThis study highlights the association of distinct cytokine profiles with migraine disease (interleukin-6, transforming growth factor-β, C-X-C motif ligand 8), migraine attacks (interleukin-1β, interleukin-6, interleukin-10) and migraine chronification (interleukin-6, adiponectin). Differences in inflammatory profiles across migraine clinical states have significant implications for understanding disease mechanisms, progression, and potential therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.